Perindopril Amlodipine for the Treatment of Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 837 participants.

Also called NCT01556997

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 837 participants (enrolled count) (from the registry)
Sponsor
Symplmed Pharmaceuticals LLC (from the registry)
Registry
  • NCT NCT01556997
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01556997. Randomized; double masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2015-08-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Perindopril Amlodipine for the Treatment of Hypertension
Acronym
PATH
Condition
Essential Hypertension
Intervention (Drug)
XOMA 985
Intervention (Drug)
Amlodipine Besylate
Intervention (Drug)
Perindopril Erbumine
Lead sponsor
Symplmed Pharmaceuticals LLC (class: industry)

Record details

Record id
cardio:ct-nct01556997
Content hash
789292ef1db22dc23a23e507cb658f3348f3914804e1273295375c6e390b7c81